Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Breast biopsy & localization · Vermont | Breast biopsy & localization · New York | |
|---|---|---|
| Surgeons, 2024 | 13 | 288 |
| Medicare fee-for-service cases | 477 | 16,847 |
| Growth since 2019 (Medicare FFS) | −0.9%/yr | +0.4%/yr |
| Forecast cases (Medicare FFS) | 1,320 in 2030 | 18,000 in 2030 |
| Forecast growth | +18%/yr to 2030 | +1.1%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 4.4 | 9.9 |
| Medicare Advantage share | 35% | 57% |
| Out of hospital | 0% (−9 pts since 2019) | 43% (+2 pts since 2019) |
| Cases per surgeon | 37 | 58 |
| Top 10 surgeons' share | 88% | 13% |
| Surgeons growing | 3 | 59 |
| New since the base year | 2 | 54 |
| Likely to stop billing it | 4 by 2026 | 29 by 2026 |
| Forecast miss, 1 year (procedure) | 3% | 3% |
| Company payments per surgeon | $28 | $2,341 |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.